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Introduction

A number of studies have demonstrated the beneficial effects of granulocyte colony-stimulating factor (G-CSF), a haematopoietic cytokine, on cardiac structure and function following acute myocardial infarction (MI) in experimental models
. Since the adverse effects of G-CSF are dose-dependent, it is noteworthy that when G-CSF was administered to animals subjected to acute MI in most of those earlier studies, the dosage seems extremely high (e.g. 100 g/kg/day) even when considering the difference in bioavailability between mice and human beings. In addition, the treatment was started at the time of coronary ligation, during reperfusion, or even before infarction. However, there are still numerous patients with acute MI who come too late to the hospital to have the chance for early coronary reperfusion. These would seem to make earlier studies clinically somewhat irrelevant. In the present study, therefore, we examined whether a small dose of G-CSF (10 g/kg/day) of which administration was begun 1 [7] , intervention not only during the acute stage but also during the subacute and chronic stages might significantly affect the post-infarction cardiac remodelling process [8, 9] . We then sought to determine which phenotypic alterations and which signal transduction pathways are critical for the G-CSF-mediated effects on hearts following MI. [3] . The same group, however, reported a critical role of activation of phosphatidyl inositol 3-phosphate (PI3K)/Akt pathway for the benefits [5, 6] . Therefore, relative importance is not known between STAT3 and Akt activations.
day after coronary occlusion could beneficially affect post-infarction cardiac function at the chronic stage (4 weeks after MI). G-CSF was instead administered for a long duration (4 weeks) based on a surmise that because myocardial infarct scar is a highly dynamic tissue
Effect of a long-term treatment with a low-dose granulocyte colony-stimulating factor on post-infarction process in the heart
Harada et al. discovered the mechanistic importance of Janus kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3) pathway activation for beneficial effects of G-CSF on postinfarction cardiac remodelling in mice
The present study therefore has two aims: (1) to examine whether treatment with a small-dose G-CSF for a long duration, started 1 day after the onset of MI, beneficially affects the postinfarction process; and (2) 
Materials and methods
Animal experiments
This study was approved by our Institutional Animal Research Committee. MI was induced in 10-week-old male C57BL/6J mice (Chubu Kagaku, Nagoya, Japan) by ligating left coronary artery as described previously [9] . We 
Physiological studies
Echocardiography and cardiac catheterization were performed before killing as previously described [9] . 
Histological analysis
Electron microscopy
The heart was minced, immersion-fixed overnight with phosphate-buffered 2.5% glutaraldehyde (pH 7.5), postfixed for 1 hr with 1% osmium tetroxide, dehydrated through a graded ethanol series and embedded in Epon medium. Ultrathin sections were stained with uranyl acetate and lead citrate and observed in an electron microscope (H700; Hitachi, Tokyo, Japan).
TUNEL at the electron microscopic level (EM-TUNEL)
EM-TUNEL was carried out as described previously [12] , after which the specimens were observed under a Hitachi 700 electron microscope.
Statistical analysis
Values were shown as mean Ϯ S.E.M. (Fig. 1C) . In the non-infarcted area, on the other hand, the Flk-1-positive vessel population tended to be greater in the G-CSFtreated group but there was no statistical difference compared with the control (Fig. 1D and Table 2 ). The ratio of vessels to a cardiomyocyte in the non-infarcted area was similar between the groups (Table 2) .
Cardiomyocyte hypertrophy was observed in the non-infarcted areas of hearts from control mice, most likely reflecting a compensatory mechanism. Somewhat unexpectedly, cardiomyocyte hypertrophy was even more pronounced in G-CSF-treated mice (Fig. 1D and (Fig. 1E) . Expression of ANP, a marker of cardiac hypertrophy [13] , was found augmented not only by induction of MI but also by G-CSF (Fig. 2A) . In addition, cardiac expression of GATA-4, a key transcriptional factor regulating the expression of sarcomeric proteins such as MHC [14] , was significantly diminished in infarcted hearts, but was significantly restored by the G-CSF treatment ( Fig. 2A) . Expression of MHC was also reduced in infarcted hearts and it, too, was restored by G-CSF. (Fig. 1B and C and Table 2 ). Western analysis showed that both MMP-2 and -9 were significantly overexpressed in G-CSF-treated hearts, as compared to control hearts (Fig. 2B) , which is consistent with an earlier report showing induction of MMP-2 and -9 by G-CSF [15] .
Fibrosis was significantly reduced in both the infarcted and noninfarcted left ventricular walls of G-CSF-treated hearts
Cardiomyocyte apoptosis
Because an anti-apoptotic effect on cardiomyocytes is reportedly one important cardioprotective mechanism of G-CSF [3] (Fig. 3A) . Electron microscopy showed the apoptotic ultrastructure of affected leucocytes, but apoptotic cardiomyocytes were never seen; only necrotic features were observed in cardiomyocytes (Fig. 3B ). Some leucocytes that had infiltrated into cardiomyocytes underwent apoptosis (Fig. 3B) , and in EM-TUNEL assays some of the necrotic cardiomyocytes were positively labelled with immunogold particles, indicating fragmented DNA (Fig. 3B) . These cells [16] . (Fig. 3D) as previously reported [10] , we found that G-CSF did not in any way modify the Fasinduced apoptosis (Fig. 3E) . (Fig. 4A) , which confirms the findings of an earlier study [3] . (Fig. 4A) . [3, 17, 18] (Fig. 4B) .
For that reason, we next assessed the incidence of apoptosis in hearts at the subacute stage of infarction (1 week after MI). We found no TUNEL-positive cardiomyocytes at this stage. Moreover, electron microscopy revealed no cardiomyocytes with apoptotic ultrastructure, though apoptotic granulation tissue cells, including macrophages, myofibroblasts and endothelial cells were detected (Fig. 3C). Likewise, no TUNEL-positive cardiomyocytes were detected in hearts at the chronic stage of infarction (4 weeks after MI).
Fig. 2 Western analysis of the effect of G-CSF on protein expression in hearts 4 weeks after MI. (A) Expression of ANP, GATA-4 and MHC. (B) Expression of MMP-2 and -9. n ϭ 4 each for the saline-treated sham, the G-CSF-treated sham and the saline-treated MI groups; n ϭ 5 for the G-CSF-treated MI
When we then directly investigated the anti-apoptotic effect of G-CSF using cultured neonatal cardiomyocytes in which apoptosis was induced by Fas stimulation
G-CSF receptor expression and downstream signal transduction
Expression of G-CSF receptors (G-CSFRs) was augmented in post-MI hearts
Fig. 4 Expression of G-CSFR and its downstream signalling in hearts and its modulation by G-CSF. (A) Western and immunohistochemical analyses of G-CSFR expression. Immunohistochemistry shows localization of G-CSFRs on cardiomyocytes, interstitial cells and endothelial cells. Arrows in the right panel indicate G-CSFR-positive endothelial cells and interstitial cells. (B) Western analysis of the expression of STAT3, Akt, ERK and their phosphorylated forms (p-STAT3, p-Akt and p-ERK). Immunohistochemistry shows the distribution of p-STAT3 and p-
Moreover, the expression was significantly up-regulated in G-CSF-treated hearts, including the sham-operated hearts, which suggests G-CSF amplifies its effects by facilitating expression of its own receptor. Immunohistochemical analysis revealed that G-CSFRs were expressed on cardiomyocytes, interstitial cells and endothelial cells in the heart
The ERK/mitogen-activated protein kinase (MAPK), JAK/STAT and PI3K/Akt pathways are known to serve as downstream mediators of G-CSFR signalling in haematopoietic cell lines and myocardium
. Western analysis of the expression levels of p-STAT3 and p-Akt showed that, following induction of MI, activation of STAT3 and Akt was more pronounced in the G-CSF-treated hearts than in controls, and that this enhancement even occurred in G-CSF-treated sham-operated hearts (Fig. 4B). On the other hand, G-CSF treatment did not affect expression of p-ERK, which was augmented in the infarcted hearts. p-STAT3 was detected immunohistochemically in cardiomyocytes and interstitial cells, while p-Akt was detected mainly in endothelial cells
Inhibition of JAK/STAT and PI3K/Akt signal activation
Given that activation of both the JAK/STAT and PI3K/Akt pathways was augmented by G-CSF treatment, we next evaluated their relative contributions to the beneficial effects in post-MI hearts. Parthenolide (1 mg/kg/day) or wortmannin (16 g/kg/day) was given to the infarct-bearing mice at the same time G-CSF was administered, whereupon they were confirmed to respectively block the G-CSF-induced activation of STAT3 and Akt in the infarcted hearts (Fig. 5). Subsequent physiological evaluation of the survivors showed that parthenolide, but not wortmannin, abolished the beneficial effects of G-CSF on cardiac remodelling and function at the chronic stage (Table 1). Histologically, parthenolide, but not wortmannin, inhibited the reduction in MI area, the exaggeration of the cardiomyocyte hypertrophy/anti-degeneration, and the reduction in myocardial fibrosis brought about by G-CSF (Table 2). On the other hand, wortmannin, but not parthenolide, inhibited G-CSFinduced vascular proliferation in the infarcted area (Table 2).
To more precisely evaluate the role of the JAK/STAT pathway in the hypertrophic/anti-degenerative effects of G-CSF, we performed an in vitro experiment using cultured cardiomyocytes. We found that both the surface area of cardiomyocytes and their expression of GATA-4 were significantly increased by the treatment with G-CSF, and those increases were completely abolished when the cells were pretreated with parthenolide or transfected with siRNA targeting STAT3, but not by wortmannin or siRNA targeting Akt-1 (Fig. 6) .
Discussion
The [19, 20] . Not all forms of cardiac hypertrophy are necessarily pathological, however, as athletic conditioning can stimulate heart growth without deleterious consequence [21] . In fact, transgenic mice that cardiospecifically overexpressed STAT3 exhibited both hypertrophy and enhanced left ventricular function [22] . [24] ; that targeted deletion of MMP-9 enhances left ventricular remodelling and collagen accumulation caused by overexpression of MMP-2 and MMP-13 [25] ; and that an increase in MMP-1 induced by hepatocyte growth factor has a beneficial effect on post-MI heart failure via its antifibrotic action [26] 
Study limitations
G-CSF was originally reported to enhance post-infarct myocardial regeneration by mobilized bone marrow-derived cells to the myocardium [1] . This effect is still controversial [1] [2] [3] [4] [5] [6] and we did not examine it in the present study. This study did not address myocardial regeneration by resident cardiac stem cells, either [28] and a possible effect of G-CSF on it remains unresolved. 
Clinical implications
